Status: Recruiting
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Acral melanoma is a melanoma that affects acral areas of the skin, which is the most prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular group,menawhile to determine the predictive value for efficiency of several biomarkers.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Di WuUpdated: May 26, 2021Locations: 1
Eligibility criteria
Peripheral blood: absolute neutrophil count (≥) 1.5 × 109 / L, platelet count (≥... [+2]
Patients who have been treated with anti-PD-1, anti-PD-L1, VEGFRTKI; [+16]